Representative images of two patients successfully treated with osimertinib following acquired resistance to icotinib.

(A) Case 1: Retroperitoneal metastasis with malignant ascites. Contrast-enhanced abdominal CT scans before osimertinib initiation (left) and after 22 months of osimertinib treatment (right). (B) Case 2: Multiple bone metastases. PET-CT scan before osime...

Full description

Saved in:

Bibliographic Details
Main Author:	Mengzhi Cheng (22648018) (author)
Other Authors:	Jianbin Zhang (230061) (author), Lili Jin (2869598) (author), Caihua Yu (715599) (author), Zhonghai Xie (22648021) (author), Dong Li (212687) (author), Qinhua Gu (361108) (author), Qibin Shen (9470343) (author)
Published:	2025
Subjects:	Medicine Cell Biology Cancer Biological Sciences not elsewhere classified osimertinib upon identification corin trial indicated central nervous system 2 adverse events retrospective study evaluated higher aes occurred although overall survival potential dfs benefit enrolled 37 patients completely resected egfr year dfs rate year disease study suggests free survival aes ), tolerated profile successfully switched risk factors nsclc ). evidence regarding adjuvant icotinib 4 %. 31 months
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Representative images of two patients successfully treated with osimertinib following acquired resistance to icotinib.

Similar Items